Ask AI
ProCE Banner Series

Optimizing TROP-2 ADC Integration in NSCLC: Evolving Evidence, Safety Management, and Sequencing in a Changing Treatment Landscape

This program examines the evolving role of TROP-2 antibody–drug conjugates (ADCs) in non-small-cell lung cancer, including emerging ESMO 2026 data, platform differences, biomarker considerations, and evidence-based treatment sequencing. Through case-based guidance, learners will explore patient selection and proactive management of TROP-2 ADC–associated toxicities, including neutropenia, diarrhea, stomatitis, ocular events, and interstitial lung disease/pneumonitis.

  AMA
  | EBAC®
Who Should Attend

This activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

All Events

Optimizing TROP-2 ADC Integration in NSCLC: Evolving Evidence, Safety Management, and Sequencing in a Changing Treatment Landscape

Upcoming Events

October

24

2026

11:00 AM - 12:30 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in applying current and emerging evidence on utilizing TROP-2 antibody–drug conjugates to improve outcomes in patients with non-small-cell lung cancer. 

Target Audience
This activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Differentiate TROP-2 ADC platforms in NSCLC based on antibody target, linker, payload, drug-to-antibody ratio, dosing schedule, evidence maturity, and expected toxicity profile
  • Assess the current limitations of TROP-2 biomarker testing and the potential future role of exploratory quantitative and computational pathology approaches in individualized treatment planning
  • Interpret recent efficacy and safety data from pivotal and emerging monotherapy and combination trials of TROP-2 ADCs, including ESMO 2026 updates, with attention to histology, genomic driver status, PD-L1 expression, prior therapy, and regulatory status
  • Develop evidence-aligned sequencing strategies that distinguish approved use, guideline-supported options, and clinical-trial opportunities for patients with advanced NSCLC after immunotherapy, chemotherapy, and/or targeted therapy
  • Apply proactive, platform-specific monitoring and multidisciplinary management strategies for TROP-2 ADC–associated adverse events, including neutropenia, diarrhea, stomatitis, ocular toxicity, and ILD/pneumonitis

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC Accreditation

Clinical Care Options, LLC dba Decera Clinical Education is an EBAC® accredited provider since 2025

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.5 hours of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA), the World Federation for Medical Education (WFME) CPD Recognition Committee, and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191